Sandoz regulatory submission for proposed biosimilar adalimumab accepted by FDA
Sandoz, a Novartis division and the global leader in biosimilar medicines, announced that the FDA has accepted its Biologics License Application, submitted under the 351 (k) pathway, for proposed biosimilar adalimumab to the reference medicine, Humira®. January 16, 2018